Anagen's flagship five-active topical. The pairwise evidence for each component is solid; the five-active combination itself isn't directly studied at this concentration — making this our most aggressive evidence-extrapolation in the catalog.
Each active in this formulation, scored against its own standalone evidence for AGA. Click any active for the full claim-by-claim breakdown.
| Active | Grade | Why it's in this formula |
|---|---|---|
| Finasteride0.1%→DHT suppression | A | Same topical 0.1% finasteride that anchors The Basics — backed by Piraccini 2022 non-inferiority data against oral 1 mg. |
| Minoxidil5%→Follicular activator | A | Standard 5% topical minoxidil. 35+ years of RCT data. Combined with finasteride here per the most-replicated AGA protocol. |
| Liothyronine (T3)6.5 ng/mL→Anagen induction | C | Microdosed T3. Mechanism is well-characterized — thyroid hormone receptors (TRα, TRβ) are expressed in human hair follicle dermal papilla, and topical T3 stimulates hair growth in animal models and ex-vivo human scalp tissue. Human RCT data at this dose for AGA specifically is limited. |
| Levocetirizine0.5%→Anti-inflammatory / anti-PGD2 | C | Levocetirizine inhibits PGD2 (elevated in bald scalp) and activates the AKT pathway in dermal papilla cells. The Zaky 2021 case-controlled study (60 men, 6 months) showed topical cetirizine 1% produced significantly higher hair regrowth on dermoscopic assessment vs control (P<0.001). |
| Latanoprost0.1%→Prostaglandin agonist | C | Latanoprost 0.1% at this concentration is the dose studied in Blume-Peytavi 2012, the only published RCT of topical latanoprost for scalp AGA — a pilot study (n=16 men, 24 weeks) showing significant hair density increase vs placebo. |
There is no published RCT of Growth Maxi as a five-active formulation. The supporting literature is per-component and per-pairing, summarized here.
Meta-analysis of 7 RCTs
396
Variable
Topical finasteride + minoxidil combination produced superior hair density (MD +9.22/cm², p=0.04), hair diameter (MD +2.26 µm, p=0.005), and global photographic assessment (MD +0.79, p<0.00001) over minoxidil alone. This is the most-replicated foundation pairing in AGA.
Randomized double-blind placebo-controlled pilot
16
24 weeks
Latanoprost 0.1% increased overall hair density and the number of vellus and terminal hairs vs placebo at 8 and 24 weeks in young men with mild AGA. Pilot scale (n=16), narrow age range (23–35) — supportive but not definitive.
Case-controlled
60
6 months
Topical cetirizine 1% applied daily produced significantly higher hair regrowth than control on dermoscopic assessment (P<0.001), with significantly higher patient satisfaction (P<0.001). Mechanism: PGD2 inhibition (PGD2 is elevated in bald scalp) and AKT pathway activation in dermal papilla cells.
Animal models and ex-vivo human scalp organ culture
Variable
Variable
Topical T3 produces dose-dependent increases in hair growth in murine models (Safer 2001) and increases the percentage of anagen hair follicles in ex-vivo human scalp tissue. TRα and TRβ are expressed in human follicle dermal papilla. Human AGA RCT data at the microdose used in Growth Maxi is limited.
Our premium suite of hair growth essentials packed into one bottle. Maximum science for maximum results.
Long-form analysis and primary-source breakdowns that go beyond the summary above.
How does Growth Maxi compare to its closest Anagen siblings?
Anagen's flagship five-active topical. The pairwise evidence for each component is solid; the five-active combination itself isn't directly studied at this concentration — making this our most aggressive evidence-extrapolation in the catalog.
Each active in this formulation, scored against its own standalone evidence for AGA. Click any active for the full claim-by-claim breakdown.
| Active | Grade | Why it's in this formula |
|---|---|---|
| Finasteride0.1%→DHT suppression | A | Same topical 0.1% finasteride that anchors The Basics — backed by Piraccini 2022 non-inferiority data against oral 1 mg. |
| Minoxidil5%→Follicular activator | A | Standard 5% topical minoxidil. 35+ years of RCT data. Combined with finasteride here per the most-replicated AGA protocol. |
| Liothyronine (T3)6.5 ng/mL→Anagen induction | C | Microdosed T3. Mechanism is well-characterized — thyroid hormone receptors (TRα, TRβ) are expressed in human hair follicle dermal papilla, and topical T3 stimulates hair growth in animal models and ex-vivo human scalp tissue. Human RCT data at this dose for AGA specifically is limited. |
| Levocetirizine0.5%→Anti-inflammatory / anti-PGD2 | C | Levocetirizine inhibits PGD2 (elevated in bald scalp) and activates the AKT pathway in dermal papilla cells. The Zaky 2021 case-controlled study (60 men, 6 months) showed topical cetirizine 1% produced significantly higher hair regrowth on dermoscopic assessment vs control (P<0.001). |
| Latanoprost0.1%→Prostaglandin agonist | C | Latanoprost 0.1% at this concentration is the dose studied in Blume-Peytavi 2012, the only published RCT of topical latanoprost for scalp AGA — a pilot study (n=16 men, 24 weeks) showing significant hair density increase vs placebo. |
There is no published RCT of Growth Maxi as a five-active formulation. The supporting literature is per-component and per-pairing, summarized here.
Meta-analysis of 7 RCTs
396
Variable
Topical finasteride + minoxidil combination produced superior hair density (MD +9.22/cm², p=0.04), hair diameter (MD +2.26 µm, p=0.005), and global photographic assessment (MD +0.79, p<0.00001) over minoxidil alone. This is the most-replicated foundation pairing in AGA.
Randomized double-blind placebo-controlled pilot
16
24 weeks
Latanoprost 0.1% increased overall hair density and the number of vellus and terminal hairs vs placebo at 8 and 24 weeks in young men with mild AGA. Pilot scale (n=16), narrow age range (23–35) — supportive but not definitive.
Case-controlled
60
6 months
Topical cetirizine 1% applied daily produced significantly higher hair regrowth than control on dermoscopic assessment (P<0.001), with significantly higher patient satisfaction (P<0.001). Mechanism: PGD2 inhibition (PGD2 is elevated in bald scalp) and AKT pathway activation in dermal papilla cells.
Animal models and ex-vivo human scalp organ culture
Variable
Variable
Topical T3 produces dose-dependent increases in hair growth in murine models (Safer 2001) and increases the percentage of anagen hair follicles in ex-vivo human scalp tissue. TRα and TRβ are expressed in human follicle dermal papilla. Human AGA RCT data at the microdose used in Growth Maxi is limited.
Our premium suite of hair growth essentials packed into one bottle. Maximum science for maximum results.
Long-form analysis and primary-source breakdowns that go beyond the summary above.
How does Growth Maxi compare to its closest Anagen siblings?
